Table 1.
Clinical characteristics of 79 Stage IV SQCLC patients.
| PI3K (N=33) | FGFR1 (N=16) | Other (N=30) | p (PI3K vs. FGFR1) | p (PI3K vs. Other) | p (FGFR1 vs. Other) | |
|---|---|---|---|---|---|---|
| Age | ||||||
| Median (range) | 68 (47–85) | 73 (48–82) | 69 (45–87) | 0.10 | 0.36 | 0.42 |
| Sex | ||||||
| Female | 48% | 44% | 30% | >0.95 | 0.20 | 0.52 |
| Smoking history (pack years) | ||||||
| Median (range) | 40 (0–90) | 43 (1–100) | 27 (0–120) | 0.63 | 0.12 | 0.12 |
| Current or former | 94% | 100% | 80% | |||
| Never | 6% | 0% | 20% | >0.95 | 0.14 | 0.08 |
| KPS | ||||||
| ≤70% | 36% | 38% | 43% | >0.95 | 0.79 | 0.052 |
| Prior lines of therapy | ||||||
| Median (range) | 1 (0–4) | 2 (0–4) | 2 (0–4) | 0.19 | 0.002 | 0.15 |
| Treated with platinum doublet | ||||||
| Proportion (%) | 21/27 (78%) | 9/13 (69%) | 20/25 (80%) | 0.70 | >0.95 | 0.069 |
| Treated with targeted therapy | ||||||
| Proportion (%) | 1/27 (4%) | 4/13 (31%) | 0 | 0.03 | -- | -- |
| Number of metastatic sites | ||||||
| >3 | 6 (18%) | 1 (6%) | 0 | 0.40 | 0.025 | 0.35 |